8 January 2020 · The below summary details the legal position regarding the sale, supply or administration of off-label/unlicensed products under Schedule 17 of the HMR 2012
16 December 2016 · The purpose of this document is to give guidance to those outsourcing PN compounding on the risks in the outsourcing and supply process and to…
1 March 2022 · National guidance from NHSE/I to reduce LASA errors and improve patient safety when considering requirements for unlicensed specials medicines
5 December 2016 · This document is aimed at staff in UK NHS hospitals considering or already sourcing their supply of chemotherapy as ready-to-administer doses.